An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Jahn, Tobias ^a   Zuther, Martin ^a   Friedrichs, Björn ^a   Heuser, Claudia ^a   Guhlke, Stefan ^a   Abken, Hinrich ^a   Hombach, Andreas A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYTOKINE ANTIBODY; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2;

ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INNATE IMMUNITY; NATURAL KILLER CELL; PROTEIN TARGETING; REED STERNBERG CELL; T LYMPHOCYTE; TARGET CELL; TUMOR LOCALIZATION; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD30; CELL LINE, TUMOR; DENDRITIC CELLS; FLOW CYTOMETRY; HODGKIN DISEASE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, SCID; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

MUS;

EID: 84866504308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044482     Document Type: Article

References (40)

1. Evens AM, Hutchings M, Diehl V, (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5: 543-556.
2. Küppers R, Schwering I, Bräuninger A, Rajewsky K, Hansmann ML, (2002) Biology of Hodgkin's lymphoma. Ann Oncol 13 Suppl 1: 11-18.
3. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, et al. (2002) Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 13 Suppl 1: 52-56.
4. Kennedy-Nasser AA, Hanley P, Bollard CM, (2011) Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol 28: 176-186.
5. Stein H, Bob R, (2009) Is Hodgkin lymphoma just another B-cell lymphoma? Curr Hematol Malig Rep 4: 125-128.
6. Newcom SR, Ansari AA, Gu L, (1992) Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell. Blood 79: 191-197.
7. van den Berg A, Visser L, Poppema S, (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 154: 1685-1691.
8. Poppema S, van den Berg A, (2000) Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 10: 345-350.
9. Skinnider BF, Mak TW, (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99: 4283-4297.
10. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, et al. (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99: 618-626.
11. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H, (2000) Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 79: 110-113.
12. Hombach A, Jung W, Pohl C, Renner C, Sahin U, et al. (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55: 830-836.
13. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, et al. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89: 2042-2047.
14. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, et al. (2001) Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7: 1873-1881.
15. Ranft K, Thepen T, Fischer R, Barth S, Stöcker M, (2009) Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells. Cancer Lett 282: 187-194.
16. Hombach A, Pohl C, Heuser C, Sircar R, Koch D, et al. (1998) Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3. Scand J Immunol 48: 497-501.
17. Hombach A, Heuser C, Abken H, (2005) Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer 115: 241-247.
18. Toennies HM, Green JM, Arch RH, (2004) Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms. J Leukoc Biol 75: 350-357.
19. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, et al. (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27: 31-39.
20. Wu C, Ferrante J, Gately MK, Magram J, (1997) Characterization of IL-12 receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is an essential component of the functional mouse IL-12 receptor. J Immunol 159: 1658-1665.
21. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, et al. (2008) Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood 111: 3377-3382.
22. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI, (1990) The impact of Hodgkin's disease on the immune system. Semin Oncol 17: 673-682.
23. Heuser C, Diehl V, Abken H, Hombach A, (2003) Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer 106: 545-552.
24. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, et al. (2002) Immunotherapy for Hodgkin's disease. Ann Hematol 81 Suppl 2: S39-42.
25. Wang B, Xiong Q, Shi Q, Le X, Xie K, (2001) Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene 20: 6930-6937.
26. Kemp RA, Ronchese F, (2001) Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167: 6497-6502.
27. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, et al. (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63: 4095-4100.
28. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, et al. (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28: 4969-4975.
29. Schliemann C, Palumbo A, Zuberbühler K, Villa A, Kaspar M, et al. (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113: 2275-2283.
30. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, et al. (2004) Potent antitumor activity of interleukin-27. Cancer Res 64: 1152-1156.
31. Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TWH, et al. (2006) Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 176: 5213-5222.
32. Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, et al. (1990) Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab′ fragments on solid human Hodgkin's disease tumors in mice. Cancer Res 50: 2929-2935.
33. Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, et al. (1993) CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int J Cancer 54: 418-425.
34. Hombach A, Pohl C, Heuser C, Sircar R, Diehl V, et al. (1998) Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies. J Immunol Methods 218: 53-61.
35. Renner C, Jung W, Sahin U, van Lier R, Pfreundschuh M, (1995) The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 25: 2027-2033.
36. Kapp U, Düx A, Schell-Frederick E, Banik N, Hummel M, et al. (1994) Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice. Ann Oncol 5 Suppl 1: 121-126.
37. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, et al. (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51: 3657-3662.
38. Heuser C, Guhlke S, Matthies A, Bender H, Barth S, et al. (2004) Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. Int J Cancer 110: 386-394.
39. Schägger H, Cramer WA, von Jagow G, (1994) Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal Biochem 217: 220-230.
40. Jost LM, Kirkwood JM, Whiteside TL, (1992) Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 147: 153-165.